Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

NCT02301130 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL: mogamulizumab
BIOLOGICAL: MEDI4736 (Durvalumab)
BIOLOGICAL: tremelimumab

Sponsor

Kyowa Kirin, Inc.

Collaborators

[object Object]